Talis Biomedical

Talis Biomedical Corp. develops and commercializes innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company was founded on June 26, 2013 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Talis Biomedical Corp. develops and commercializes innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company was founded on June 26, 2013 and is headquartered in Chicago, IL.

Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific

Talis Biomedical Announces First Quarter 2021 Financial Results and Business Progress

Camden National

Malvern Bancorp

Signify Health

According to Insider Cluster Buys, a Premium feature of GuruFocus, four stocks with a high number of unique insider buys during February and March are Camden National Corp. (NASDAQ:CAC), Talis Biomedical Corp. (NASDAQ:TLIS), Signify Health Inc. (NYSE:SGFY) and Malvern Bancorp Inc. (NASDAQ:MLVF).

4 Stocks With High Insider Cluster Buys During February and March

Bumble

Fiserv

Anterix Inc

Corvus Pharmaceuticals

Decibel Therapeautics

Molecular Templates

NexImmune

Oncorus

Prothena

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.

The Past Week's Notable Insider Buys: More Biotech IPOs, Bumble, Fiserv And More

MENLO PARK, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced the closing of its previously announced initial public offering of 15,870,000 shares of its common stock, which includes 2,070,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $16.00 per share. Including the option exercise, the aggregate gross proceeds to Talis from the offering were approximately $253.9 million, before deducting the underwriting discounts and commissions and offering expenses. The shares began trading on The Nasdaq Global Market on February 12, 2021, under the ticker symbol “TLIS.”

Talis Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

News for Talis Biomedical Stock (TLIS)